[Results of clinical trials with the new prostaglandin E2-derivative Nalador (sulproston)].
D000019:Abortifacient Agents / Q000494:pharmacology; D002986:Clinical Trials as Topic; D015232:Dinoprostone / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology
D000019:Abortifacient Agents; D011459:Prostaglandins E, Synthetic; C016767:sulprostone; D015232:Dinoprostone
Ergebnisse der klinischen Prüfung des neuen Prostaglandin E2-Derivats Nalador (Sulproston).